Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
11:00am, Friday, 03'rd Nov 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AAS
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
07:34pm, Monday, 30'th Oct 2023
Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
01:32pm, Monday, 30'th Oct 2023
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
07:33pm, Tuesday, 24'th Oct 2023
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.
7 Healthcare Stocks to invest in for a Healthy Future
08:45am, Friday, 20'th Oct 2023
One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.
GILD or VRTX: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 19'th Oct 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option
Dividend Income Update September 2023
08:30pm, Tuesday, 17'th Oct 2023
With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs
07:16am, Tuesday, 17'th Oct 2023
Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with an initial focus in hepatitis B virus and hepatiti
Gilead Sciences Stock Is Cheap, With Broad Pipeline
09:45pm, Sunday, 15'th Oct 2023
Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis C, and cancer. In Q2 2023, Gilead Sciences report
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now
10:00am, Sunday, 15'th Oct 2023
Pfizer is on a roll of important approvals that will eventually fill the gap left by its coronavirus portfolio. Gilead Sciences has a deep lineup and pipeline that are especially concentrated around H
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
04:05pm, Thursday, 12'th Oct 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
05:40am, Tuesday, 10'th Oct 2023
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for ly
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
07:16am, Thursday, 05'th Oct 2023
The risk to the market is mounting, and with it, volatility. The VIX is up nearly 50% in the last month and heading higher, which means the S&P 500 could be heading lower.
Gilead Sciences: A Healthy Buy With Solid Dividend
09:00am, Wednesday, 04'th Oct 2023
Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last 'Buy' rating in August last year. Yet, the stock trades at a low PE ratio, especially after trading down over the pas
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from its virology research and development programs that will be presented at IDWeek 2023, October 1
